Terms: = Thyroid cancer AND MECOM, MDS1-EVI1, EVI1, 2122, ENSG00000085276, Q03112, PRDM3 AND Prognosis
2 results:
1. PAX8 and mecom are interaction partners driving ovarian cancer.
Bleu M; Mermet-Meillon F; Apfel V; Barys L; Holzer L; Bachmann Salvy M; Lopes R; Amorim Monteiro Barbosa I; Delmas C; Hinniger A; Chau S; Kaufmann M; Haenni S; Berneiser K; Wahle M; Moravec I; Vissières A; Poetsch T; Ahrné E; Carte N; Voshol J; Bechter E; Hamon J; Meyerhofer M; Erdmann D; Fischer M; Stachyra T; Freuler F; Gutmann S; Fernández C; Schmelzle T; Naumann U; Roma G; Lawrenson K; Nieto-Oberhuber C; Cobos-Correa A; Ferretti S; Schübeler D; Galli GG
Nat Commun; 2021 Apr; 12(1):2442. PubMed ID: 33903593
[TBL] [Abstract] [Full Text] [Related]
2. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract] [Full Text] [Related]
